Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Capital Expenditures (2021 - 2025)

Core Scientific's Capital Expenditures history spans 5 years, with the latest figure at $279.2 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 523.28% year-over-year to $279.2 million; the TTM value through Dec 2025 reached $729.0 million, up 315484.42%, while the annual FY2025 figure was $729.0 million, 315484.42% up from the prior year.
  • Capital Expenditures for Q4 2025 was $279.2 million at Core Scientific, down from $449.7 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $449.7 million in Q3 2025 and bottomed at -$176.2 million in Q3 2022.
  • The 5-year median for Capital Expenditures is $15.3 million (2023), against an average of $42.5 million.
  • The largest annual shift saw Capital Expenditures crashed 530.6% in 2024 before it soared 110400.0% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$116.1 million in 2021, then tumbled by 51.8% to -$176.2 million in 2022, then soared by 108.7% to $15.3 million in 2023, then plummeted by 530.6% to -$66.0 million in 2024, then soared by 523.28% to $279.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Capital Expenditures are $279.2 million (Q4 2025), $449.7 million (Q3 2025), and -$83.9 million (Q2 2025).